The takeaway
Abivax SA American Depositary Shares shows a pronounced seasonal pattern over 3 years of data — strongest in February (+16.3%) and softest in July (−12.9%).
Right now
In July, the stock has fallen 0% of years, averaging −12.9%, roughly 15.1 pts behind the S&P 500.
The full picture
Abivax SA American Depositary Shares's most dependable month has been February, higher in 2 of 2 years; July has been its least reliable, up just 0% of the time.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Win rate % | ||||||||||||
| Median return % | ||||||||||||
| 2025 | — | |||||||||||
| 2024 | ||||||||||||
| 2023 | — | — | — | — | — | — | — | — | — |
Month by month
The stock's clearest edge over the S&P 500 lands in February (+16.5 pts); it has trailed the market most in July (−15.1 pts).
“vs S&P” is Abivax SA American Depositary Shares’s average for a month minus the S&P 500’s average for that same month — isolating Abivax SA American Depositary Shares’s own seasonal edge from broad market drift.
Reality check
Not enough recent February history to say whether the pattern still holds.
Figures are the typical (median) February return and how often it rose — the last 2 years versus the last 3(the heatmap’s default window). This verdict stays anchored to that 3-year window even if you zoom the chart, so it never disagrees with the badges above.
In plain English
Strip the year back and a single month does the heavy lifting: February, up in all 2 Februaries while the other eleven tend to blur together.
Its average (+16.3%) and median (+16.3%) land within a hair of each other — the tell of steady, year-after-year gains rather than one outlier doing the work. That reliability comes with real swings, mind — even February ranges by 13.0% from year to year, so any single year can land far from the average. Crucially, the gain is the stock's own rather than a rising tide's: February has cleared the S&P 500 by +16.5 points above the index. It bucks the broad tape, besides: February lifts just 49% of stocks across the market.
A few other months pull their weight: April, August, and November have also closed higher more often than not. On the other side of the ledger, July has been the soft spot — the weakest of 5 months that average a loss (−12.9%), and the edge isn't year-round — the stock has trailed the S&P 500 in July, May, and March. Its roughest month on record was a −20.7% October in 2023 — a reminder of how hard even a seasonal name can fall.
The takeaway is less about when to buy than what to expect: February aside, the stock's months offer little reliable tilt. With a short 3-year record, the signal is best held loosely.
Short answers on the stock's best month (February), its worst (July), and whether it really trades seasonally.
Yes, to a pronounced degree. Since 2023 its best month (February, +16.3%) has run well ahead of its worst (July, −12.9%) — the heatmap above shows how steady that gap has been year to year.
February has been the strongest, averaging +16.3% and closing higher in all 2 years on record since 2023.
It's the weakest, averaging −12.9% — historically a soft spot, though it still varies from year to year.
Explore
These names have the strongest July track records on record — a starting point for comparison.
Before you trade